Korro Bio

About:

Korro Bio provides an efficient and selective method for RNA editing, leveraging natural processes common to all multi-cellular organisms.

Website: https://www.korrobio.com

Twitter/X: KorroBio

Top Investors: Blue Owl, Alexandria Venture Investments, Fidelity, Cormorant Asset Management, New Enterprise Associates

Description:

Korro Bio provides an efficient and selective method for RNA editing, leveraging natural processes common to all multi-cellular organisms. Korro Bio was created to lead the field of RNA editing. The company is advancing a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in protein structure and function across multiple tissues. In 2018,

Total Funding Amount:

$278M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Cambridge, Massachusetts, United States

Founded Date:

2018-01-01

Founders:

Andrew Fraley, Nessan Bermingham

Number of Employees:

51-100

Last Funding Date:

2024-04-18

IPO Status:

Public

Industries:

© 2025 bioDAO.ai